-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Givinostat Hydrochloride in Duchenne Muscular Dystrophy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Givinostat Hydrochloride in Duchenne Muscular Dystrophy report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Givinostat Hydrochloride in Duchenne Muscular Dystrophy Drug Details: Givinostat...
-
Product Insights
Becker Muscular Dystrophy – Drugs In Development, 2023
Global Markets Direct’s, ‘Becker Muscular Dystrophy - Drugs In Development, 2023’, provides an overview of the Becker Muscular Dystrophy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Becker Muscular Dystrophy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Sevasemten in Duchenne Muscular Dystrophy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sevasemten in Duchenne Muscular Dystrophy report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sevasemten in Duchenne Muscular Dystrophy Drug Details: Sevasemten (EDG-5506) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Sevasemten in Becker Muscular Dystrophy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sevasemten in Becker Muscular Dystrophy report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sevasemten in Becker Muscular Dystrophy Drug Details: Sevasemten (EDG-5506) is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Sevasemten in Limb-Girdle Muscular Dystrophy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Sevasemten in Limb-Girdle Muscular Dystrophy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Sevasemten in Limb-Girdle Muscular Dystrophy Drug Details: Sevasemten (EDG-5506) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Azenosertib in Osteosarcoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Azenosertib in Osteosarcoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Azenosertib in Osteosarcoma Drug Details: Azenosertib (ZNC-3) is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Apitegromab in Obesity
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Apitegromab in Obesity report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Apitegromab in Obesity Drug Details: Apitegromab (SRK-015) is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Froniglutide in Inclusion Body Myositis (IBM)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Froniglutide in Inclusion Body Myositis (IBM) Drug Details: Froniglutide (formerly PB-1023) is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ARM-210 in Ventricular Tachycardia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ARM-210 in Ventricular Tachycardia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ARM-210 in Ventricular Tachycardia Drug Details: ARM-210 is under development for...